Lasofoxifene (ELAINE Program)
Locally advanced or metastatic ER+/HER2- breast cancer with ESR1 mutation
Key Facts
About Sermonix Pharmaceuticals
Sermonix Pharmaceuticals is a clinical-stage biotech targeting a high-unmet need in women's oncology: advanced ER+/HER2- breast cancer that has developed ESR1 mutations after prior therapy. The company's sole clinical asset, lasofoxifene, is a selective estrogen receptor modulator (SERM) with unique tissue selectivity and is currently being evaluated in the pivotal Phase 2 ELAINE studies against the standard of care, fulvestrant. As a private company, Sermonix is positioned to advance this targeted therapy through clinical development, with the goal of providing a new oral treatment option for a genetically defined patient population that currently has limited effective therapies.
View full company profileTherapeutic Areas
Other Locally advanced or metastatic ER+/HER2- breast cancer with ESR1 mutation Drugs
| Drug | Company | Phase |
|---|---|---|
| Lasofoxifene + Abemaciclib (ELAINE-2) | Sermonix Pharmaceuticals | Phase 2 |